曹晓静,李妍,魏莹,赵朕龙,伍洁,彭丽丽,于明安.微波消融治疗继发性甲状旁腺功能亢进症的有效性和安全性:Meta分析[J].中国介入影像与治疗学,2021,18(10):577-582
微波消融治疗继发性甲状旁腺功能亢进症的有效性和安全性:Meta分析
Efficacy and safety of microwave ablation for secondary hyperparathyroidism: Meta-analysis
投稿时间:2021-05-19  修订日期:2021-07-24
DOI:10.13929/j.issn.1672-8475.2021.10.001
中文关键词:  甲状旁腺功能亢进症,继发性  超声检查  微波消融  荟萃分析
英文关键词:hyperparathyroidism, secondary  ultrasonography  microwave ablation  meta-analysis
基金项目:首都临床特色应用研究项目(Z181100001718135)、中日友好医院院级科研基金(2019-2-HL-4)。
作者单位E-mail
曹晓静 中日友好医院介入医学科, 北京 100029  
李妍 中日友好医院介入医学科, 北京 100029  
魏莹 中日友好医院介入医学科, 北京 100029  
赵朕龙 中日友好医院介入医学科, 北京 100029  
伍洁 中日友好医院介入医学科, 北京 100029  
彭丽丽 中日友好医院介入医学科, 北京 100029  
于明安 中日友好医院介入医学科, 北京 100029 yma301@163.com 
摘要点击次数: 764
全文下载次数: 262
中文摘要:
      目的 系统评价微波消融(MWA)治疗继发性甲状旁腺功能亢进症(SHPT)的有效性和安全性。方法 检索PubMed、Cochrane Library、Embase、中国知网和万方医学网自建库至2020年12月31日发表的MWA治疗SHPT相关文献。采用Stata 15.0软件分析MWA治疗SHPT的有效性和安全性。结果 依据纳入及排除标准,最终纳入9篇文献、共249例SHPT患者。与消融前相比,MWA后1天[加权均数差(WMD)=1 142.04,95%CI(783.03,1 501.06),P<0.001]、1周[WMD=859.85,95%CI(758.97,960.74),P<0.001]、1个月[WMD=800.29,95%CI(687.12,913.47),P<0.001]和6个月[WMD=857.09,95%CI(746.07,968.11),P<0.001]的甲状旁腺激素(PTH)水平均显著降低;MWA后1天[WMD=0.39,95%CI(0.33,0.45),P<0.001;WMD=0.29,95%CI(0.16,0.41),P<0.001]和1周[WMD=0.23,95%CI(0.02,0.43),P<0.05;WMD=0.31,95%CI(0.02,0.61),P<0.05]钙和磷水平均下降。MWA后神经损伤发生率为1.20%[效应量(ES)=0.02,95%CI(-0.00,0.05),P>0.05],低钙血症发生率为21.69%[ES=0.60,95%CI(0.39,0.81),P<0.001],声音嘶哑发生率为5.62%[ES=0.06,95%CI(0.03,0.09),P<0.001],血肿发生率为1.61%[ES=0.03,95%CI(-0.01,0.06),P=0.095]。结论 MWA治疗SHPT有效且安全。
英文摘要:
      Objective To systematically evaluate the efficacy and safety of microwave ablation (MWA) for treatment of secondary hyperparathyroidism (SHPT). Methods PubMed, Embase, Cochrane Library, CNKI and Wanfang Med Online were searched for relevant literatures published before December 31, 2020. Then Stata 15.0 software was used for meta-analysis in evaluating the efficacy and safety of MWA for treatment of SHPT. Results According to the inclusion and exclusion criteria, a total of 249 patients from 9 articles were enrolled in this study. Compared with pre-ablation, the levels of parathyroid hormone (PTH) were significantly lower 1 day (weighted mean difference[WMD]=1 142.04, 95%CI [783.03, 1 501.06], P<0.001), 1 week (WMD=859.85, 95%CI [758.97,960.74], P<0.001), 1 month (WMD=800.29, 95%CI[687.12, 913.47], P<0.001) and 6 months (WMD=857.09, 95%CI[746.07, 968.11], P<0.001) after MWA, while the levels of calcium and phosphorus were significantly lower 1 day (WMD=0.39, 95%CI [0.33,0.45], P<0.001; WMD=0.29, 95%CI [0.16, 0.41], P<0.001) and 1 week (WMD=0.23, 95%CI [0.02, 0.43], P<0.05; WMD=0.31, 95%CI [0.02, 0.61], P<0.05) after MWA. The incidence of nerve injury was 1.20% (effect size[ES]=0.02, 95%CI [-0.00, 0.05], P>0.05) after MWA, of hypocalcemia was 21.69% (ES=0.60, 95%CI [0.39,0.81], P<0.001), of voice hoarse was 5.62% (ES=0.06, 95%CI [0.03, 0.09], P<0.001), and of hematoma was 1.61% (ES=0.03, 95%CI [-0.01, 0.06], P=0.095). Conclusion MWA was effective and safe for treating SHPT.
查看全文  查看/发表评论  下载PDF阅读器
关闭